1 / 5

Prostate Cancer Diagnostics Market

Prostate Cancer Diagnostics Market<br>

swati15
Download Presentation

Prostate Cancer Diagnostics Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Prostate Cancer Diagnostics Market To Reach USD 7,112.2 Million By 2027

  2. Market Summary The global prostate cancer diagnostics market is forecasted to reach USD 7,112.2 Million by 2027, according to a new report by Reports and Data. The prostate cancer diagnostics market is observing demand attributed to the rising incidence of prostate cancer. It is the most common cause of death occurring as a result of cancer in American men. It has been found that nearly 1 out of 41 men die of prostate cancer. According to recent estimations, around 33,330 men will die of the disease in the year 2020. Increasing awareness about cancer diagnosis at an early stage is a significant factor driving the market growth. A majority of prostate cancers or about 90.0% cases are detected when the disease is in the prostate gland and the nearby organs, and for such cases, the 5-year survival rate is about 100.0%, whereas the 5-year survival rate for the cases in which the disease has spread to other body parts is 31.0%. The COVID-19 impact:The COVID-19 pandemic has made it essential to repurpose the operating rooms for surgeries into intensive care units (ICUs) and pushed hospitals to accommodate patients beyond their full capacity of beds. As a result, in several cases, cancer patients' diagnostics and treatment were categorized as non-urgent. Further, the psychological influence of postponed diagnosis as a result of the COVID-19 pandemic cannot be undermined as when psychological, physical, and social health of patients are handled in a positive way, chances of patients’ survival have been seen to improve from a state of illness towards recovering from the disease. COVID-19 has had a significant and negative impact on cancer treatment and research, making a new health emergency for cancer patients’ management a necessity.

  3. Market Summary • Further key findings from the report suggest • Adenocarcinomas develop in the cells of the gland, which line the prostate gland and are the most commonly occurring prostate cancer, with about everyone suffering from the disease has this type. • PCA3 is a biomarker beneficial in improving the precision of prostate cancer diagnostics. The biomarker is preferred, due to its fairly high sensitivity and specificity during the diagnostic procedures. • Hospitals & clinics dominated the market in 2019. The factors including well-resourced operating & diagnostic rooms, higher purchasing power, the existence of highly skilled healthcare professionals, and improved health coverage for hospital-based healthcare services from several private and group insurance plans, among others, are responsible for the high market share of hospitals. • North America contributed to the largest market share in 2019. The market dominance is owing to the higher acceptance of advanced technologies, well-established healthcare diagnostic facilities, the surging incidence of prostate cancer, and the enactment of numerous initiatives for raising awareness about the disease in the region. • Key participants include Abbott Laboratories, Siemens Healthineers, F. Hoffman La Roche Ltd., Danaher Corporation, Agilent Technologies, Myriad Genetics Inc., Becton, Dickinson, and Company, Diasorin SPA, Genomic Health, and Beckman Coulter Inc., among others.

  4. Market Summary For the purpose of this report, Reports and Data has segmented into the global prostate cancer diagnostics on the basis of prostate cancer type, test type, end-user, and region: Prostate Cancer Type Outlook (Revenue, USD Billion; 2017-2027) Acinar Adenocarcinoma Ductal Adenocarcinoma Transitional Cell (or Urothelial) Cancer Squamous Cell Cancer Small Cell Prostate Cancer Others Test Type Outlook (Revenue, USD Billion; 2017-2027) Preliminary Tests Confirmatory Tests End-User Outlook (Revenue, USD Billion; 2017-2027) Hospitals & Clinics Diagnostic Centers Research Institutes

  5. About US Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Contact US John Watson Head of Business Development Reports And Data | Web: www.reportsanddata.com Direct Line: +1-212-710-1370 E-mail: sales@reportsanddata.com

More Related